Table 1.
CAV1 in cytoplasm and stroma in relation to patient and tumor characteristics.
| All patients | Missing | CAV1 cytoplasm n = 886 |
CAV1 stroma n = 915 |
Patients with non-evaluable TMAs |
||||
|---|---|---|---|---|---|---|---|---|
| Negative | Positive | Not strong | Strong | CAV1 cytoplasmic | CAV1 Stroma | |||
| n = 1018 | n = 493 (55.6%) | n = 393 (44.4%) | n = 575 (62.8%) | n = 340 (37.2%) | n = 132 | n = 103 | ||
| Number (%) | Number (%) | Number (%) | Number (%) | Number (%) | Number (%) | Number (%) | ||
| or Median (IQR) | or Median (IQR) | or Median (IQR) | or Median (IQR) | or Median (IQR) | or Median (IQR) | or Median (IQR) | ||
| Age at inclusion, years | 61.1 (52.1–68.1) | 0 | 60.9 (52.7–68.4) | 61.3 (51.2–67.7) | 61.8 (53.9–68.4) | 58.7 (50.0–67.4) | 61.1 (51.6–68.3) | 63.3 (54.1–70.2) |
| BMI ≥25 kg/m2 | 503 (50.8) | 28 | 240 (50.1) | 196 (51.4) | 283 (50.2) | 160 (49.4) | 67 (51.5) | 60 (58.8) |
| Waist circumference ≥80 cm | 731 (74.6) | 38 | 345 (72.5) | 289 (77.1) | 414 (74.3) | 240 (74.3) | 97 (75.2) | 77 (77.0) |
| Breast volume ≥850 ml | 492 (57.3) | 160 | 225 (53.4) | 201 (61.3) | 272 (56.3) | 166 (57.8) | 66 (60.6) | 54 (61.4) |
| Alcohol abstainer, yes | 106 (10.4) | 3 | 53 (10.8) | 41 (10.5) | 57 (10.0) | 42 (12.4) | 12 (9.1) | 7 (6.8) |
| Preoperative smoker, yes | 206 (20.3) | 2 | 98 (19.9) | 76 (19.4) | 111 (19.3) | 71 (20.9) | 32 (24.2) | 24 (23.3) |
| Coffee, ≥2 cups/day | 824 (80.9) | 0 | 391 (79.3) | 324 (82.4) | 483 (84.0) | 262 (77.1) | 109 (82.6) | 79 (76.7) |
| Oral contraceptives, ever | 722 (71.0) | 1 | 354 (72.0) | 274 (69.7) | 412 (71.7) | 241 (71.1) | 91 (71.2) | 69 (70.0) |
| Menopausal hormone therapy, ever | 447 (44.0) | 3 | 229 (46.5) | 158 (40.4) | 265 (46.3) | 139 (41.0) | 60 (45.5) | 43 (41.8) |
| Hormonal intrauterine device, ever | 166 (16.6) | 18 | 81 (16.7) | 63 (16.3) | 75 (13.3) | 72 (21.8) | 22 (16.9) | 19 (18.5) |
| Age at menarche, years | 13 (12–14) | 6 | 13 (12–14) | 13 (12–14) | 13 (12–14) | 13 (12–14) | 13.5 (13–14) | 13 (13–14) |
| Nulliparous | 122 (12.0) | 0 | 52 (10.6) | 54 (13.7) | 67 (11.7) | 42 (12.4) | 16 (12.1) | 13 (12.6) |
| Screening detected (age 45–74 years) | 569 (66.2) | 159 | 261 (62.3) | 221 (67.8) | 317 (63.5) | 189 (68.7) | 87 (76.3) | 63 (74.1) |
| Invasive tumor size | 0 | |||||||
| >20 mm (or muscular or skin involvement) | 277 (27.2) | 149 (30.2) | 99 (25.2) | 168 (29.2) | 82 (24.1) | 29 (22.0) | 27 (26.2) | |
| Any axillary lymph node involvement | 389 (38.3) | 2 | 207 (42.1) | 139 (35.5) | 219 (38.2) | 138 (40.6) | 43 (32.6) | 32 (31.1) |
| Receptor status | ||||||||
| ER+ | 894 (87.9) | 1 | 468 (94.3) | 312 (79.6) | 491 (85.5) | 314 (92.4) | 114 (86.4) | 89 (86.4) |
| PR+ | 721 (70.9) | 1 | 376 (76.3) | 255 (65.1) | 389 (67.8) | 253 (74.4) | 90 (68.2) | 79 (76.7) |
| HER2 Amplification | 110 (11.5) | 63 | 56 (11.9) | 37 (9.6) | 69 (12.6) | 31 (9.3) | 17 (17.2) | 10 (14.1) |
| Triple Negative | 74 (7.3) | 7 | 10 (2.0) | 58 (14.8) | 50 (8.7) | 19 (5.6) | 6 (4.7) | 5 (5.1) |
| Main histological type | 0 | |||||||
| No special type (formerly ductal) | 823 (80.8) | 393 (79.7) | 337 (85.8) | 466 (81.0) | 285 (83.8) | 93 (70.5) | 72 (69.9) | |
| Lobular | 117 (11.5) | 72 (14.6) | 21 (5.3) | 72 (12.5) | 33 (9.7) | 24 (18.2) | 12 (11.7) | |
| Other or mixed | 78 (7.7) | 28 (5.7) | 35 (8.9) | 37 (6.4) | 22 (6.5) | 15 (13.4) | 19 (18.5) | |
| Histological grade | 1 | |||||||
| I | 256 (25.2) | 125 (25.4) | 89 (22.7) | 126 (21.9) | 96 (28.3) | 42 (32.1) | 34 (33.0) | |
| II | 504 (49.6) | 267 (54.2) | 174 (44.3) | 295 (51.3) | 166 (49.0) | 63 (48.1) | 43 (41.8) | |
| III | 257 (25.3) | 101 (20.5) | 130 (33.1) | 154 (26.8) | 77 (22.7) | 26 (19.9) | 26 (25.2) | |
| Ever treatment by last follow-up prior to any event | ||||||||
| Chemotherapy | 259 (25.4) | 0 | 117 (23.7) | 113 (28.8) | 148 (25.7) | 87 (25.6) | 29 (22.0) | 24 (23.3) |
| Radiotherapy | 644 (63.3) | 0 | 318 (64.5) | 253 (64.4) | 359 (62.4) | 228 (67.1) | 73 (55.3) | 57 (55.3) |
| Herceptin | 73 (7.2) | 0 | 38 (7.7) | 22 (5.6) | 46 (8.0) | 19 (5.6) | 13 (9.9) | 8 (7.8) |
| ER+tumors | ||||||||
| Tamoxifen | 572 (64.0) | 0 | 315 (67.3) | 195 (62.5) | 318 (64.8) | 201 (64.0) | 62 (54.4) | 53 (59.6) |
| Aromatase inhibitor | 371 (41.5) | 0 | 211 (45.1) | 119 (38.1) | 223 (45.4) | 119 (36.0) | 41 (36.0) | 35 (39.3) |